NASDAQ: LYCALycia Therapeutics Inc Stock
$30.00
Updated Oct 23, 2026
LYCA Price
$30.00
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$22.19
52 Week High
$36.49
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.09
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LYCA Overview
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LYCA's potential to beat the market
- LYCA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LYCA
RankedUnranked of 455
RankedUnranked of 455
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.02 | A | |
| $125.63 | A | |
| $10.08 | A |
Be the first to know about important LYCA news, forecast changes, insider trades & much more!
LYCA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LYCA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LYCA's short-term assets ($127.72M) exceed its short-term liabilities ($10.14M)
Short-term Liabilities Financials
LYCA's short-term assets ($127.72M) exceed its long-term liabilities ($1.71M)
Long-term Liabilities Financials
LYCA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LYCA due diligence checks available for Premium users.
Valuation
LYCA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$156.8M
Liabilities
$11.8M
Debt to equity
-0.09
LYCA's short-term assets ($127.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LYCA's short-term assets ($127.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LYCA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LYCA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Lycia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.